背景:本研究旨在研究高粘度diquafosol四钠(DQS)眼用溶液(DIQUASLX;DQSLX)的耐受性,并检查其可用性和对干眼症(DED)患者临床表现的影响。
方法:这项介入回顾性研究包括66例DED患者的66只眼,这些患者从常规DQS转为DQSLX眼用溶液。撕裂功能评估(泪膜破裂时间[BUT],角膜结膜重要染色[VS]评分),DED症状缓解的评估,和四项可用性问卷(“灌输后的舒适度,滴注后的“\”刺激,“\”眼粘液排出,“\”滴注频率的便利性\”)使用视觉模拟量表从0(最差)到10(最佳)进行评估,在切换到DQSLX后4周。使用多元回归分析评估与药物耐受性相关的因素。
结果:转用DQSLX后症状改善64.2%。BUT值,VS得分,切换到DQSLX后,问卷项目“滴注时的舒适度”和“滴注频率的便利性”显着提高。据报道,DQSLX耐受性在56例(84.8%)患者中可接受,在10例(15.2%)患者中不可接受。总的来说,DQSLX耐受性与“滴注时的舒适度”和“滴注频率的便利性”显着相关,并且倾向于与VS评分≥1相关。DQSLX的耐受性取决于症状和VS评分的改善以及VS评分≥1的患者(39例)没有过度的“眼粘液排出”,但在VS评分=0的患者(27名患者)中,“滴注后舒适”和没有过多的“眼粘液排出”。
结论:高粘度DQSLX滴眼液在研究人群中通常被认为是可接受的。然而,有和没有上皮损伤的DED患者之间的药物耐受性似乎有所不同。前者受到症状和临床表现改善的影响,而后者在灌输时受到安慰的影响。
背景:大学医院医疗信息网络标识符,UMIN000051390。
BACKGROUND: This study aimed to investigate the tolerability of high-viscosity diquafosol tetrasodium (DQS) ophthalmic solution (DIQUAS LX; DQSLX) and examine its usability and effect on clinical findings in patients with dry eye disease (DED).
METHODS: This interventional retrospective study included 66 eyes of 66 patients with DED who switched from conventional DQS to DQSLX ophthalmic solution. Tear function assessments (tear film breakup time [BUT], keratoconjunctival vital staining [VS] score), evaluations of DED symptom relief, and a four-item usability questionnaire (\"comfort upon instillation,\" \"irritation upon instillation,\" \"eye mucus discharge,\" \"convenience of instillation frequency\") assessed using a visual analog scale from 0 (worst) to 10 (best) were administered 4 weeks after switching to DQSLX. Factors associated with drug tolerability were assessed using multiple regression analysis.
RESULTS: The symptoms improved by 64.2% after switching to DQSLX. The BUT value, VS score, and the questionnaire items \"comfort upon instillation\" and \"convenience of instillation frequency\" were significantly improved after switching to DQSLX. DQSLX tolerability was reported as acceptable in 56 (84.8%) and unacceptable in 10 (15.2%) patients. Overall, DQSLX tolerability was significantly associated with \"comfort upon instillation\" and \"convenience of instillation frequency\" and tended to be associated with a VS score ≥ 1. DQSLX tolerability depended on symptom and VS score improvements and absence of excessive \"eye mucus discharge\" in patients with a VS score ≥ 1 (39 patients), but on \"comfort upon instillation\" and absence of excessive \"eye mucus discharge\" in patients with a VS score = 0 (27 patients).
CONCLUSIONS: The high-viscosity DQSLX ophthalmic solution was generally considered acceptable in the study population. However, drug tolerability seemingly differed between patients with DED with and without epithelial damage. The former were affected by improvements in symptoms and clinical findings, whereas the latter were affected by comfort upon instillation.
BACKGROUND: University Hospital Medical Information Network identifier, UMIN000051390.